GlobeNewswire: Plus Therapeutics Inc. Contains the last 10 of 259 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T19:17:42ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/27/2853110/0/en/Plus-Therapeutics-to-Present-at-the-National-Comprehensive-Cancer-Network-Annual-Conference.html?f=22&fvtc=4&fvtv=30698Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference2024-03-27T12:00:00Z<![CDATA[AUSTIN, Texas, March 27, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that it will present a poster at the National Comprehensive Cancer Network (NCCN) 2024 Annual Conference, which will be held April 5-7, 2024, in Orlando, Florida.]]>https://www.globenewswire.com/news-release/2024/03/25/2851568/0/en/Plus-Therapeutics-Announces-Validation-Clinical-Implementation-of-CSF-01-Leptomeningeal-Cancer-Cell-Diagnostic.html?f=22&fvtc=4&fvtv=30698Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic2024-03-25T12:00:00Z<![CDATA[Plus’ CSF-01 cancer cell enumeration test is a sensitive and specific diagnostic test for the presence of adenocarcinoma and melanoma cancer cells in the leptomeninges]]>https://www.globenewswire.com/news-release/2024/03/11/2843624/0/en/Plus-Therapeutics-Completes-Dosing-in-Cohort-5-of-ReSPECT-LM-Phase-1-Trial-of-Rhenium-186Re-Obisbemeda-in-Leptomeningeal-Metastases.html?f=22&fvtc=4&fvtv=30698Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases2024-03-11T11:00:00Z<![CDATA[A total of 18 patients have been dosed in the trial to date]]>https://www.globenewswire.com/news-release/2024/03/05/2840902/0/en/Plus-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Business-Highlights.html?f=22&fvtc=4&fvtv=30698Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights2024-03-05T21:05:00Z<![CDATA[Began enrollment of the 5th of an anticipated 7 planned dosing cohorts for the ReSPECT-LM Phase 1 dose escalation trial with rhenium (186Re) obisbemeda for leptomeningeal metastases (LM)]]>https://www.globenewswire.com/news-release/2024/02/27/2835968/0/en/Plus-Therapeutics-to-Announce-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Host-Conference-Call-on-March-5-2024.html?f=22&fvtc=4&fvtv=30698Plus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 20242024-02-27T13:00:00Z<![CDATA[AUSTIN, Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will report fourth quarter and full year 2023 financial results on Tuesday, March 5, 2024, after market close. Plus Therapeutics’ management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update.]]>https://www.globenewswire.com/news-release/2023/12/18/2797674/0/en/Plus-Updates-Financial-and-Cash-Guidance-for-2024.html?f=22&fvtc=4&fvtv=30698Plus Updates Financial and Cash Guidance for 20242023-12-18T12:00:00Z<![CDATA[Plus Receives $3.3M in grant revenue in Q4 2023]]>https://www.globenewswire.com/news-release/2023/12/12/2794712/0/en/Plus-Therapeutics-Partners-With-K2bio-for-Development-of-Novel-Tests-for-Cerebrospinal-Fluid-CSF-Tumor-Cell-and-Molecular-Biomarker-Analyses.html?f=22&fvtc=4&fvtv=30698Plus Therapeutics Partners With K2bio for Development of Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker Analyses2023-12-12T13:00:00Z<![CDATA[Collaboration to explore novel CSF cancer testing modalities and initial testing panel to be available in Q1 2024 for ReSPECT-LM patients Collaboration to explore novel CSF cancer testing modalities and initial testing panel to be available in Q1 2024 for ReSPECT-LM patients]]>https://www.globenewswire.com/news-release/2023/11/29/2787710/0/en/Plus-Therapeutics-to-Present-at-the-5th-Targeted-Radiopharmaceuticals-Summit-Europe.html?f=22&fvtc=4&fvtv=30698Plus Therapeutics to Present at the 5th Targeted Radiopharmaceuticals Summit Europe2023-11-29T13:00:00Z<![CDATA[AUSTIN, Texas, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that Marc H. Hedrick, M.D., President and Chief Executive Officer, will deliver a presentation at the 5th Targeted Radiopharmaceuticals Summit Europe, being held December 5-7, 2023 in Berlin, Germany.]]>https://www.globenewswire.com/news-release/2023/11/20/2783115/0/en/Plus-Therapeutics-Reports-New-Interim-ReSPECT-GBM-Phase-2-Trial-Data-at-the-Society-for-NeuroOncology-Annual-Meeting-and-will-Host-Key-Opinion-Leader-Webinar.html?f=22&fvtc=4&fvtv=30698Plus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar2023-11-20T12:00:00Z<![CDATA[Median overall survival (mOS) in 15 patients with recurrent glioblastoma (rGBM) from the Phase 2 study is 13 months, which is 63% better than current standard of care (bevacizumab monotherapy) of 8 months; 9 of the 15 patients remain alive]]>https://www.globenewswire.com/news-release/2023/11/15/2780882/0/en/Plus-Therapeutics-to-Host-Virtual-KOL-Event-on-New-Phase-2-ReSPECT-GBM-Data-in-Recurrent-Glioblastoma-Presented-at-the-Society-for-NeuroOncology-SNO-Conference-on-Monday-November-2.html?f=22&fvtc=4&fvtv=30698Plus Therapeutics to Host Virtual KOL Event on New Phase 2 ReSPECT-GBM Data in Recurrent Glioblastoma Presented at the Society for NeuroOncology (SNO) Conference on Monday, November 20, 20232023-11-15T12:00:00Z<![CDATA[AUSTIN, Texas, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced it will host a virtual KOL event on Monday, November 20, 2023 at 10:00 AM ET to discuss new Phase 2 ReSPECT-GBM data in recurrent glioblastoma presented at the Society for NeuroOncology (SNO) Conference. To register, click here.]]>